One of the most compelling breakthroughs involves the engineering of CAR T cells to target uPAR, a surface protein intricately involved in tissue remodeling and wound healing. This protein’s persistent overexpression in tumor cells and supportive cells within the tumor microenvironment renders it an ideal immunotherapeutic target. Preclinical studies demonstrated that uPAR-directed CAR T cells effectively shrink solid tumors across lung, pancreatic, and ovarian cancer models in mice, even eliminating metastases in certain cases. This dual-action targeting disrupts not only the malignant cells but also the fibrotic and immunosuppressive stroma, a barrier that has notoriously hindered immunotherapy efficacy in solid tumors. Remarkably, these engineered cells spare normal immune counterparts, suggesting a promising therapeutic window and underscoring the potential expansion of CAR T therapies beyond hematologic malignancies.

MSK’s work transcends traditional tumor-centric views by framing cancer as a complex, interconnected ecosystem of malignant cells and their microenvironmental niches. The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project, under the scientific guidance of Scott Lowe, PhD, epitomizes this approach. By unraveling the interactive cellular and molecular networks sustaining tumor growth, this initiative seeks to pioneer therapies that dismantle not only cancer cells but also their protective microenvironments. Such integrated strategies could revolutionize the management of historically intractable cancers.

Harnessing cutting-edge computational biology, Dana Pe’er, PhD, and colleagues unveiled how select cancer cell subtypes orchestrate their surroundings to establish a self-perpetuating tumor ecosystem. Utilizing spatial transcriptomics coupled with an innovative algorithm termed Wasserstein Wormhole, they delineated how ‘basal’ cancer cells attract myeloid immune populations that fortify the tumor’s defenses. Ablation of these basal cells in murine pancreatic cancer models resulted in ecosystem collapse, rendering tumors vulnerable to immune attack. These insights reveal that targeting cellular heterogeneity and intercellular communication within tumors can disarm the cocooning microenvironment that fosters therapeutic resistance.

Further computational dissection revealed highly plastic progenitor-like cancer cells in early pancreatic tumors that, when unchecked by tumor suppressor p53, fuel malignant progression through reprogramming their niche. This discovery clarifies the pivotal tumor-suppressive role of p53 in curbing cellular plasticity, offering new angles for therapeutic intervention aimed at reestablishing tissue homeostasis and thwarting early oncogenesis.

Immunomodulatory dynamics within tumors also received critical scrutiny, as Omar Abdel-Wahab, MD, presented pioneering research on the role of RNA splicing in mediating T cell exhaustion—a phenomenon that limits the efficacy of immunotherapies like checkpoint inhibitors. His team uncovered unique RNA splice variants in CD8+ T cells infiltrating melanoma, distinct from those in functional T cells. By manipulating RNA splicing pathways, they enhanced the anti-tumor capability of exhausted T cells, offering a molecular blueprint for reinvigorating immune responses and overcoming immune evasion in tumors.

The challenge of therapeutic resistance was starkly illuminated in the context of HER2-targeted antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd). Sarat Chandarlapaty, MD, PhD, alongside Joshua Drago, MD, MS, probed tumor biopsies from patients who relapsed following T-DXd treatment. Their analyses revealed two dominant resistance mechanisms: downregulation or loss of HER2 expression and mutational alterations that hinder ADC binding. Importantly, co-targeting HER2 and the alternative antigen TROP2 with combined ADC regimens achieved superior efficacy in preclinical models, suggesting a translational path towards overcoming resistance and refining targeted therapy paradigms.

In a novel exploration of tissue-level protection against cancer, Mara Sherman, PhD, focused on the pancreas’ mesenchymal stroma and its secretion of KITL, a signaling molecule crucial for maintaining tissue architecture and limiting cellular plasticity. Loss of KITL was observed during early stages of pancreatic tumorigenesis, facilitating cell state changes that promote malignancy. Sherman’s findings underscore the importance of stromal-tumor interactions and hint at preventive strategies that bolster tissue integrity to counteract cancer initiation.

Broader genomic investigations highlighted the influence of hereditary genetics beyond mere cancer susceptibility to encompass tumor evolution and mutational landscapes. Jian Carrot-Zhang, PhD, presented a compelling study demonstrating that inherited germline variants shape which somatic mutations tumors acquire. This multi-ancestral analysis unveiled population-specific genetic influences, emphasizing the necessity for personalized medicine approaches that account for genetic diversity and its impact on tumor biology and treatment responsiveness.

Another striking advance pertained to the body’s response to viral infections associated with cancer risk. Computational biologist Caleb Lareau, PhD, revealed how persistent Epstein-Barr virus (EBV) infection—implicated in autoimmune diseases and cancers—is modulated by host genetic variants identified through large-scale genomic and viral DNA data mining. By integrating data from hundreds of thousands of individuals, this research identified specific genetic loci linked to EBV persistence and related chronic diseases, opening avenues for targeted interventions aiming to mitigate virus-associated cancer risk.

Harmonizing these multifaceted discoveries, MSK’s research demonstrates unparalleled integration of molecular biology, computational science, immunology, and clinical insights. The collective efforts presented at AACR 2026 not only deepen our mechanistic understanding of cancer as a dynamic ecosystem but also propel the field toward innovative therapeutic strategies designed to disrupt tumor support networks, overcome resistance, and personalize treatment based on genetic and molecular cancer ecosystems.

In sum, the 2026 AACR Annual Meeting illuminated the future trajectory of oncology: a landscape where cutting-edge bioengineering, high-resolution spatial profiling, RNA biology, and germline-genome interactions converge to transform cancer diagnosis, prevention, and therapy. With these insights, MSK and collaborators are charting a bold course toward more effective and durable cancer treatments, fostering hope for patients facing some of the most formidable malignancies.

Subject of Research: Cancer Biology and Therapeutics, Tumor Microenvironment, Immuno-Oncology, Computational Oncology, Genetic Determinants of Cancer Progression, Resistance Mechanisms, Viral Oncology

Article Title: Emerging Paradigms in Cancer Ecosystems and Therapeutics: Insights from Memorial Sloan Kettering at AACR 2026

News Publication Date: 2026

Web References:

• https://www.aacr.org/meeting/aacr-annual-meeting-2026
• https://www.mskcc.org/news/treating-her2-amplified-early-stage-rectal-cancer-to-improve-quality-of-life
• https://www.mskcc.org/news/new-kras-targeted-therapy-shows-promise-against-pancreatic
• https://www.mskcc.org/news/can-mrna-vaccines-fight-pancreatic-cancer-msk-clinical-researchers-are-trying-find-out

References:

• Cell (2026) on engineered uPAR-targeting CAR T cells and spatial transcriptomics studies
• Cancer Discovery (2026) on resistance mechanisms to HER2-targeted ADCs
• Nature (2025) on genetic determinants of Epstein-Barr virus persistence

Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Cancer Ecosystems, CAR T Cell Therapy, Tumor Microenvironment, RNA Splicing, Immunotherapy Resistance, HER2 Antibody-Drug Conjugates, Pancreatic Cancer, Genetic Variation, Epstein-Barr Virus, Computational Biology, Spatial Transcriptomics

Cancers of unknown primary represent a daunting clinical puzzle. These metastatic malignancies disguise their origins, leaving physicians to treat them without definitive knowledge of their tissue of origin. This uncertainty severely hampers personalized treatment, often relegating patients to broad-spectrum chemotherapy regimens that tend to yield poorer survival outcomes compared to therapies directed at the known primary cancer site. The work of Dr. De Velasco and his colleagues directly confronts this challenge by tapping into molecular biology’s subtleties to provide a clearer map back to the cancer’s source.

The core innovation lies in targeting CpG sites—regions in the genome where cytosine and guanine nucleotides are connected by a phosphate bond and can be chemically modified by methyl groups. This methylation process varies significantly among tissue types and persists even as cancer cells metastasize. By analyzing methylation profiles at these sites, the research team developed a machine learning algorithm that discerns tissue-specific methylation signatures, effectively turning the epigenome into a barcode of cancer identity. Unlike traditional genomic sequencing that focuses on mutations, this epigenetic approach captures a layer of regulation vital for understanding cancer heterogeneity.

To build this model, the researchers aggregated methylation data from nearly 7,500 cancer patients spanning 21 distinct cancer types, sourced from the Cancer Genome Atlas (TCGA) and other public repositories. Through rigorous computational training, the model learned to associate specific CpG methylation patterns with corresponding cancer types. Crucially, rather than saturating the analysis with vast data from hundreds of thousands of CpG loci, the algorithm distilled the predictive signature down to approximately 1,000 strategically chosen CpG regions. This focused approach maintains predictive strength while enhancing clinical feasibility for eventual diagnostic application.

Evaluation of the model’s performance was striking. On a designated test cohort, the machine learning system accurately identified the cancer origin in roughly 95% of cases. When further challenged with an independent validation cohort comprising 31 patients with 17 varied cancer types, it sustained an impressive accuracy rate of around 87%. These findings signify a substantial leap toward practical application, affirming that epigenomic markers can reliably inform the tissue of origin even in complex clinical scenarios.

One of the transformative implications of this study is its potential to shift the paradigm in managing CUP patients. By pinpointing the likely cancer origin, physicians could tailor therapies more precisely, moving away from generalized chemotherapy regimens toward targeted treatments proven to extend patient survival. Current statistics underscore this need, with site-specific treatments enabling survival up to 24 months, while nonspecific approaches yield median survival times of only six to nine months.

Despite its promise, the research team acknowledges that the current model was trained predominantly on cancers with established primaries, rather than true CUP cases. This distinction necessitates further validation through prospective clinical trials enrolling patients whose primary tumor site remains elusive despite exhaustive diagnostic workup. Such studies will be critical to ascertain the model’s robustness and clinical utility in real-world oncology practice.

Additionally, tissue accessibility presents a logistical challenge. Advanced-stage tumors, often buried deep within the body, can be difficult or risky to biopsy. Responding to this obstacle, Dr. De Velasco highlighted an important next frontier: adapting the model to analyze circulating tumor DNA (ctDNA) obtained via minimally invasive liquid biopsies. This technique captures fragments of tumor DNA circulating in the bloodstream, enabling genetic and epigenetic profiling without the need for direct tissue sampling and opening new avenues for widespread clinical deployment.

Moreover, the choice to focus on DNA methylation confers significant advantages over gene expression profiling or mutation analysis alone. Methylation patterns are generally more stable across cellular states and less influenced by tumor microenvironment or transient gene activity changes. This stability enhances the reliability of the biomarker and may facilitate longitudinal monitoring of tumor evolution and response to therapy.

This pioneering use of adaptive systems and machine learning in cancer epigenetics exemplifies the convergence of computational biology and clinical oncology. By distilling vast molecular datasets into actionable diagnostic signatures, the research not only enhances our biological understanding but also lays the groundwork for personalized cancer care that can improve survival outcomes and quality of life.

Funding for this innovative study was provided by the Japan Society for the Promotion of Science. Importantly, Dr. De Velasco reported no conflicts of interest, reinforcing the scientific integrity of this work. As the field advances, continued collaboration across genomics, bioinformatics, and clinical disciplines will be essential to translate these findings into clinical tools that can revolutionize CUP diagnosis and treatment worldwide.

In conclusion, the successful application of machine learning to CpG DNA methylation profiles represents a major milestone in oncology diagnostics. This approach offers a promising, accessible pathway toward resolving the enigmatic origins of cancers of unknown primary, ultimately enabling more effective, tailored treatments and improving patient prognoses. The research community eagerly anticipates forthcoming clinical trials that will validate and refine this technology, potentially bringing precision medicine to previously intractable cancer cases.

Subject of Research: Machine learning application in CpG DNA methylation profiling for tissue-of-origin prediction in cancers of unknown primary.

Article Title: (Information not provided)

News Publication Date: (Information not provided)

Web References: American Association for Cancer Research (AACR) Annual Meeting 2026 – https://www.aacr.org/meeting/aacr-annual-meeting-2026/

References: (Not explicitly detailed in the source material)

Image Credits: (Not provided)

Keywords: Machine learning, CpG DNA methylation, cancers of unknown primary, cancer diagnostics, epigenetics, tissue-of-origin prediction, computational biology, adaptive systems, personalized medicine, circulating tumor DNA, liquid biopsy, Cancer Genome Atlas